Peder M. Andersen
MBA,
Chief Executive Officer |
Tine Kold Olesen
PhD, MBA COO
Chief Operation Officer |
Niels Laursen
MBA,
Chief Financial Officer |
Leila Malik
PhD,
Chief Development Officer |
- Peder Andersen holds 1,196,405 shares and 56,500 Investor warrants through his wholly owned company Fred Management ApS
- Peder Andersen holds 1 139 905 shares through his wholly owned company Fred Management ApS
- Chief Executive Officer at Biosergen AS since 2017
- As CEO at Forward Pharma from 2012-2017, he was heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq (USD 235m)
- Managing director at Forward Pharma GmbH from 2009-2016
- Vice President of clinical development at Astion Pharma from 2010-2012
|
- Senior roles with experience from directing global, integrated development programs from early clinical stage to life cycle management primarily in the field of urology/oncology (Ferring 19 Years). The responsibilities included design and execution of novel strategies from early (first in man) stage through marketing authorization with key focus on CMC, clinical development, and regulatory interactions.
- Junior roles within neurology (Novo nordisk, Glaxo Welcome and Orion)
- Vice President in the development of biosimilars and active in alliance management (Alvotech 2 years)
|
- Niels Laursen holds 20,000 shares and 20,000 Investor warrants
- Currently Owner at Dwork, offering Strategic consulting and business development
- Formerly CFO at Oncology Venture
- CFO at Medical Prognosis Institute
- Healthcare Innovation Manager at Blue Ocean Robotics
- Director HR at TopoTarget A/S
|
- Leila Malik has more than 20 years of experience within biotech and pharmaceutical companies (Zealand Pharma, Ferring, Ionis Pharmaceutical)
- Senior roles in CMC development across the development life cycle from precandidate selection to commercial support with both pre-clinical and regulatory
interactions
- Junior roles include process and product development for several therapeutics within various decease
|
- Doctor of Medicine (MD) from Copenhagen University
|
- PhD. Medical and Health Sciences, Ghent University
- MSc. Pharmaceutical Sciences, Copenhagen University
- MBA. COO. Imperial College, London
|
- MBA, cand.merc from Copenhagen Business School
|
- Master degree in Organic Chemistry and a Ph.D in Bioorganic Chemistry from
University of Copenhagen
|
